Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. BIOAF


Primary Symbol: V.BTI

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bioasis Technologies Inc. > Prothena and Management's Reporting
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(625)
•••
Comment by KayakerBCon Oct 01, 2022 12:58pm
140 Views
Post# 34999455

RE:RE:RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

RE:RE:RE:RE:RE:RE:RE:RE:RE:Prothena and Management's ReportingIt's simple. Bioasis can give guidance on the capabilities of xB3 and on whether and when it expects an IND submission to be made by anybody.

Oh Geez, C'mon.  Bioasis should state it EXPECTS an IND submission and WHEN? Puleeeeeeeze.  They would have to rely on what the pharma SAID they were going to do.  No company would EVER do that.  And if the submission didn't happen or didn't happen when they said, you'd be saying Bioasis misled investors.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities